Mayo Clinic | Strategic Alliance Partners

February 06, 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

February 06, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

January 30, 2024

Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease.

January 30, 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

January 30, 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

January 24, 2024

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

January 23, 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

January 23, 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

January 23, 2024

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

January 17, 2024

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.

January 16, 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

January 16, 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

January 15, 2024

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

January 12, 2024

Sikander Ailawadhi, MD, shares considerations for the potential sequencing of bispecific antibodies and other BCMA-directed therapies in multiple myeloma.

January 10, 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

January 08, 2024

Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.

January 08, 2024

Iopofosine I 131 monotherapy elicited durable responses and was associated with a tolerable safety profile in patients with heavily pretreated, multi-class refractory Waldenström macroglobulinemia.

January 07, 2024

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

January 05, 2024

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.